AstraZeneca PLC stock (US6549022043): London shares edge higher after CARES Phase III update

AstraZeneca PLC shares in the United Kingdom traded slightly higher after the company reported positive topline Phase III CARES data for anselamimab, adding fresh momentum to the LSE-listed stock on 05/29/2026.

AstraZeneca PLC shares on the London Stock Exchange ticked up on 05/29/2026 after the United Kingdom-based pharmaceutical group released positive topline Phase III results from its CARES program evaluating anselamimab in a rare disease setting, providing a fresh fundamental catalyst for the LSE:AZN stock according to coverage from ad-hoc-news and other market sources as of 05/29/2026.

The company, whose primary listing is on the London Stock Exchange and which is a key constituent of major UK equity benchmarks, said the global CARES Phase III clinical program showed that treatment with anselamimab led to what it described as nominally significant improvements versus control, reinforcing its strategic push in immunology and rare disease therapies and drawing investor attention to the potential future revenue contribution of this pipeline asset.

The stock traded around the mid-130 pounds level on the London Stock Exchange on 05/29/2026, with quotes near £138 intraday according to UK market data, while US investors access the equity primarily via the NYSE-listed ADR under the ticker AZN, reflecting AstraZeneca PLC's position as a cross-listed global large-cap in the United Kingdom and the United States.

The positive CARES Phase III topline readout came against a backdrop of sustained interest in AstraZeneca PLC within the UK equity market, where the company remains one of the largest healthcare names by market capitalization and a core component of institutional portfolios, and the incremental data around anselamimab added to the broader narrative of the group expanding beyond its established oncology franchise into additional high-value specialty areas.

In Germany, AstraZeneca PLC also changes hands on venues such as Tradegate, where the shares are quoted in euros and give local investors indirect access to the London-listed stock, offering a bridge between the United Kingdom home market and a wider European retail investor base following the CARES program update.

The CARES Phase III results are particularly relevant for UK and international investors because late-stage trial outcomes often influence expectations for future launches and potential regulatory filings, and the nominally positive efficacy signals reported for anselamimab in the CARES program on 05/29/2026 may feed into updated sell-side financial models and scenario analyses as analysts refine their revenue projections for AstraZeneca PLC's mid-term pipeline.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: AstraZeneca
• Sector/industry: Biopharmaceuticals and prescription medicines
• Headquarters/country: Cambridge, United Kingdom
• Core markets: Europe, United States, emerging markets
• Key revenue drivers: Oncology, cardiovascular, renal and metabolism, respiratory, immunology and rare disease therapies
• Home exchange/listing venue: London Stock Exchange (AZN)
• Trading currency: GBP

AstraZeneca PLC: core business model

AstraZeneca PLC focuses on discovering, developing and commercializing innovative prescription medicines across oncology, cardiovascular, renal, metabolism, respiratory, immunology and rare disease indications, with growth driven by a portfolio of patent-protected drugs and a late-stage pipeline aimed at expanding treatment options in critical therapeutic areas.

What banks and research houses say about AstraZeneca PLC

According to MarketBeat data as of 05/29/2026, AstraZeneca PLC carries a consensus rating of "Moderate Buy" from six analysts, with an average 12-month price target of £153.33 compared with a spot price around £138.02, implying expectations of further upside over the coming year based on the latest compiled research views.

Within that consensus range, the highest published target stands at £180 and the lowest at £115 as of 05/29/2026, illustrating that while there is broad positive sentiment toward the AstraZeneca PLC investment case in the analyst community, there is also dispersion around how strongly individual research houses believe in the company's prospective earnings and cash-flow trajectory following recent pipeline updates such as the CARES Phase III anselamimab data.

Conclusion

The modest uplift in AstraZeneca PLC's London Stock Exchange share price on 05/29/2026 following the positive topline CARES Phase III results for anselamimab underlines how closely UK investors track late-stage pipeline news in shaping their view of the stock's long-term earnings power.

Combined with a "Moderate Buy" consensus rating and an average 12-month price target of £153.33 from six analysts as of 05/29/2026, the CARES program data provide additional context for how the market is assessing AstraZeneca PLC's balance between existing marketed products and future growth drivers emerging from its late-stage clinical portfolio.

For investors monitoring the United Kingdom blue-chip healthcare space, the interplay between ongoing trial readouts like CARES and evolving analyst expectations will remain central to understanding how AstraZeneca PLC's valuation develops over time within both its London home market and its US ADR listing.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.